Cardiovascular adverse events (CVAEs) are of considerable importance in patients with multiple myeloma (MM), given the significant prevalence of coexisting cardiovascular risk factors and the potential treatment-induced toxicity. Brugada syndrome is a rare cardiological disease responsible for arrhythmia and potentially fatal cardiac arrest. Brugada phenocopies (BrP) are clinical entities which show an identical ECG patterns, but prompt resolution after treatment of the trigger event. A 65-year-old female newly diagnosed MM patient treated with a carfilzomib-based chemotherapy developed a type 1 Brugada ECG pattern during a hospitalization course for sepsis. As fever and the septic event resolved, further ECGs showed no abnormalities and carfilzomib-based treatment could be resumed with no further CVAEs. Though fever-induced BrP is a universally known phenomenon, to our knowledge this is the first case of BrP in a patient with MM during active treatment with carfilzomib.

Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report

Ghisoni, Eleonora;Marandino, Laura;Lombardi, Pasquale;Becco, Paolo;Aglietta, Massimo;Gay, Francesca;
2019

Abstract

Cardiovascular adverse events (CVAEs) are of considerable importance in patients with multiple myeloma (MM), given the significant prevalence of coexisting cardiovascular risk factors and the potential treatment-induced toxicity. Brugada syndrome is a rare cardiological disease responsible for arrhythmia and potentially fatal cardiac arrest. Brugada phenocopies (BrP) are clinical entities which show an identical ECG patterns, but prompt resolution after treatment of the trigger event. A 65-year-old female newly diagnosed MM patient treated with a carfilzomib-based chemotherapy developed a type 1 Brugada ECG pattern during a hospitalization course for sepsis. As fever and the septic event resolved, further ECGs showed no abnormalities and carfilzomib-based treatment could be resumed with no further CVAEs. Though fever-induced BrP is a universally known phenomenon, to our knowledge this is the first case of BrP in a patient with MM during active treatment with carfilzomib.
143
25
481-485
485
https://www.karger.com/Article/Abstract/502538
Brugada phenocopies; Brugada syndrome; Carfilzomib; Myeloma
Ghisoni, Eleonora; Marandino, Laura; Lombardi, Pasquale; Bonzano, Alessandro; Becco, Paolo; Aglietta, Massimo; Fizzotti, Marco; Gay, Francesca; Rota Scalabrini, Delia
File in questo prodotto:
File Dimensione Formato  
[Publisher Version] Ghisoni et al - 2019 - Safe Use of Carfilzomib - Case Report.pdf

Accesso riservato

Descrizione: [Publisher Version] Ghisoni et al - 2019 - Safe Use of Carfilzomib - Case Report
Tipo di file: PDF EDITORIALE
Dimensione 325.89 kB
Formato Adobe PDF
325.89 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1712708
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact